Oligonucleotide drug development is on a steady increase as more therapies are being discovered.  CMIC has experience supporting hundreds of studies for oligonucleotide-based drugs, including: qualification, full method validation and GLP sample analysis. Our experience includes decoy, antisense, siRNA and aptamer.

Since 2012, CMIC has supported hundreds of studies for oligonucleotide-based drugs, including: qualification, full method validation and GLP sample analysis for oligonucleotide-based drugs, in various tissues, urine and plasma for preclinical and clinical studies.

  • Partnered with recognized global leaders in RNA-targeted discoveries
  • Nearly 100 individual compounds successfully validated since 2012
  • Vast experience with chemically modified oligonucleotides including GalNAc conjugate, cholesterol conjugate, thymidylic acid and phosphate
Experience PlatformsCapabilitiesBiomatrix
Decoy
Antisense
siRNA
Aptamer
HPLC-UV, Hybridization,
LC-MS/MS, HPLC-FD,
LC-HRMS, qPCR,
ECL
Method transfer, development & qualification, validation, Quantitative bioanalysis, Metabolite ID & confirmationPlasma/Serum, Blood, Urine, CSF, Muscle, Liver, Kidney, Lung, Brain, Heart, Tumor Tissue, PBMC, Ocular

Bioanalysis & GLP Analytical Services

Small Molecule Bioanalysis

Large Molecule Bioanalysis

Biomarkers